Category - Developments

Avivagen (TSX-V:VIV) has made the first industrial-scale sale of its OxC-beta livestock to UNAHCO in the Philippines. The sale is for 150 kilograms of OxC-beta livestock 10% premix at pricing in line with...

Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the “12 Most Important Innovations of the Year” in the health category in Popular Science’s annual Best of...

Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials – OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic...

3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company’s first step toward validation and approval of...

Avivagen (TSX-V:VIV) has agreed to supply OxC-beta Livestock to UNAHCO for sales and distribution in the Republic of the Philippines. OxC-beta has been shown to be effective and economic in replacing the antibiotics...

Microbix Biosystems (TSX:MBX) expects to report revenue in the range of $3.3-million for the fiscal fourth quarter ended Sept. 30, 2016, an increase of 57% from $2.1-million in the year earlier quarter. Fourth quarter...

Profound Medical (TSX-V:PRN) has entered into an agreement with a syndicate of underwriters, led by GMP Securities, for a bought deal of 15.82 million common shares at a price of $1.10 each for gross proceeds of $17.4...

Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids. Independent TV station, WHDT...

Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular...

The U.S. Patent and Trademark Office has issued a patent to Mateon Therapeutics (NASDAQ:MATN) and Baylor University that covers compounds which modulate cathepsin activity, particularly cathepsin L or cathepsin K, and...